Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results ...

Nevro (NVRO) shares ended the last trading session 13.9% higher at $5.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Scavilla confirmed the acquisition of Nevro Corporation for $250 million, expanding Globus Medical's reach into the musculoskeletal market, particularly in neuromodulation technology and chronic ...